RxDoctor Payments Data

Michaela Johnson, APRN

Nurse Practitioner · Salt Lake City, UTNPI 1275094369

Payments from drug & device makers

$1,827in general payments, 2019–2025

Across 30 payments — averaging $60.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$322
  • Boston Scientific$210
  • E.r. Squibb & Sons, L.L.C.$202
  • Medtronic$164
  • Amgen$141
  • Merck$132
  • plus $656 from 8 others

What the payments were for

  • Speaking & faculty fees$845%
  • Food & beverage$1,74395%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,827 in reported general payments places this provider in the 85th percentile of 979 nurse practitioner providers in Utah.

See all nurse practitioner providers in Utah

Medicare billing

Part B allowed, 2024
$46,675
Medicare patients
374
Services billed
515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban84$108,010
XareltoRivaroxaban28$41,387
JardianceEmpagliflozin16$20,500
Repatha SureclickEvolocumab26$16,541
VascepaIcosapent Ethyl16$16,367
Repatha SyringeEvolocumab11$15,212
Ezetimibe184$5,317
Rosuvastatin Calcium312$5,201
Metoprolol Succinate332$4,994
Atorvastatin Calcium396$4,710
Telmisartan90$2,725
Amlodipine Besylate295$2,017
ClopidogrelClopidogrel Bisulfate138$1,781
Lisinopril195$1,698
Carvedilol152$1,582

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$81$41,38728 claims
Boehringer IngelheimJardiance$48$20,50016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 979 nurse practitioner providers in Utah.

Other nurse practitioner in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →